We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Novel Molecular Signaling Pathway Inhibits Lung Cancer Growth and Metastasis

By LabMedica International staff writers
Posted on 23 Nov 2015
A gene that had not been linked previously to lung cancer was found to be a critical component of a novel molecular signaling pathway that restricts lung cancer progression and metastasis.

Investigators at Northwestern University (Evanston, IL, USA) based the current study on emerging evidence that the neuronal guidance molecule SLIT played a role in tumor suppression, as SLIT-encoding genes were found to be inactivated in several types of cancer, including lung cancer. More...
The SLIT gene produces the protein Slit, which in conjunction with the protein Robo (Roundabout) constitute a cell signaling pathway with many diverse functions including axon guidance and angiogenesis. Slit refers to a secreted protein which is most widely known as a repulsive axon guidance cue and Robo to its transmembrane protein receptor.

The investigators reported in the November 3, 2015, online edition of the Journal of Clinical Investigation that SLIT inhibited cancer cell migration by activating RhoA. RhoA (Ras homolog gene family, member A) is a small GTPase protein known to regulate the actin cytoskeleton in the formation of stress fibers. This protein is essential for the signaling function of the Rho GTPase complex.

The investigators found that myosin 9b (Myo9b) was a ROBO-interacting protein that suppressed RhoA activity in lung cancer cells. X-ray crystallography structural analyses revealed that the RhoGAP domain of Myo9b contained a unique patch that specifically recognized RhoA. The ROBO intracellular domain interacted with the Myo9b RhoGAP domain and inhibited its activity. Therefore, SLIT-dependent activation of RhoA was mediated by ROBO inhibition of Myo9b. In a mouse model, compared with control lung cancer cells, SLIT-expressing cells had a decreased capacity for tumor formation and lung metastasis.

In lung cancer cells, the intracellular domain (ICD) of ROBO directly interacted with the Myo9b RhoGAP domain and inhibited its activity. Thus, the negative regulation of Myo9b by SLIT/ROBO signaling in lung cancer cells activated RhoA and inhibited cell migration. Supporting this model, the data showed that SLIT inhibited lung tumor invasion and metastasis in a xenograft mouse model. Furthermore, Myo9b was highly expressed in human lung cancer tissues as compared with levels observed in the control samples. Consistently, increased Myo9b expression was associated with lymph node metastasis, advanced tumor stage, and poor patient survival.

These results implicate the existence of a previously unknown SLIT/ROBO/Myo9b/RhoA signaling pathway that inhibits cell migration and suppresses lung cancer metastasis.

“Elevated Myo9b expression is associated with fast lung cancer progression and poor prognosis,” said senior author Dr. Jane Wu, professor of neurology and psychiatry at Northwestern University. “These observations suggest the exciting possibility of developing Myo9b as a new biomarker for cancer, especially lung cancer. Our study provides new insights into the molecular and cellular mechanisms underlying lung cancer invasion and metastasis, a critical process that often leads to fatal consequence. Our data also provide a solid foundation for developing new diagnostic and therapeutic tools for lung cancer.”

Related Links:

Northwestern University



Gold Member
Hematology Analyzer
Medonic M32B
Collection and Transport System
PurSafe Plus®
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
ESR Analyzer
TEST1 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The enhanced collaboration builds upon the successful launch of the AmplideX Nanopore Carrier Plus Kit in March 2025 (Photo courtesy of Bio-Techne)

Bio-Techne and Oxford Nanopore to Accelerate Development of Genetics Portfolio

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded its agreement with Oxford Nanopore Technologies (Oxford, UK) to broaden Bio-Techne's ability to develop a portfolio of genetic products on Oxford... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.